Novo Nordisk's (NOVOB DC) CagriSema 2.4 did not meet the primary endpoint of showing non-inferiority on weight loss vs tirzepatide 15mg at 84 weeks
Importance
Level 1
- CagriSema achieved 23% weight loss after 84 weeks of treatment, tirzepatide achieved 25.5%.
- CagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84 weeks.
- Additional trials are exploring the full weight loss potential of CagriSema, including higher-dose combinations.
#NOVO NORDISK A/S#NOVOB.DC#IMPORTANT#EU SESSION#EUROPEAN EQUITIES